| norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis P Fickert, GM Hirschfield, G Denk, HU Marschall, I Altorjay, M Färkkilä, ... Journal of hepatology 67 (3), 549-558, 2017 | 262 | 2017 |
| Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study W Reinisch, W de Villiers, L Bene, L Simon, I Rácz, S Katz, I Altorjay, ... Inflammatory bowel diseases 16 (2), 233-242, 2010 | 249 | 2010 |
| PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis J Trebicka, J Fernandez, M Papp, P Caraceni, W Laleman, C Gambino, ... Journal of hepatology 74 (5), 1097-1108, 2021 | 185 | 2021 |
| New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a … M Papp, I Altorjay, N Dotan, K Palatka, I Foldi, J Tumpek, S Sipka, ... Official journal of the American College of Gastroenterology| ACG 103 (3 …, 2008 | 176 | 2008 |
| A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED) W Reinisch, M Staun, RK Tandon, I Altorjay, AV Thillainayagam, ... Official journal of the American College of Gastroenterology| ACG 108 (12 …, 2013 | 174 | 2013 |
| Utility of serological markers in inflammatory bowel diseases: gadget or magic? M Papp, GL Norman, I Altorjay, PL Lakatos World journal of gastroenterology: WJG 13 (14), 2028, 2007 | 166 | 2007 |
| Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections M Papp, Z Vitalis, I Altorjay, I Tornai, M Udvardy, J Harsfalvi, A Vida, ... Liver International 32 (4), 603-611, 2012 | 144 | 2012 |
| Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised … BE Sands, PM Irving, T Hoops, JL Izanec, LL Gao, C Gasink, ... The Lancet 399 (10342), 2200-2211, 2022 | 119 | 2022 |
| Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease A Tromm, I Bunganič, E Tomsová, Z Tulassay, M Lukáš, J Kykal, ... Gastroenterology 140 (2), 425-434. e1, 2011 | 119 | 2011 |
| Hypertriglyceridemia-induced acute pancreatitis: A prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases D Mosztbacher, L Hanák, N Farkas, A Szentesi, A Mikó, J Bajor, P Sarlós, ... Pancreatology 20 (4), 608-616, 2020 | 113 | 2020 |
| Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ... Inflammatory bowel diseases 17 (3), 767-777, 2011 | 98 | 2011 |
| In vivo target sites of nitric oxide in photosynthetic electron transport as studied by chlorophyll fluorescence in pea leaves B Wodala, Z Deák, I Vass, L Erdei, I Altorjay, F Horváth Plant Physiology 146 (4), 1920-1927, 2008 | 94 | 2008 |
| Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype … M Papp, I Altorjay, GL Norman, Z Shums, K Palatka, Z Vitalis, I Foldi, ... Inflammatory bowel diseases 13 (8), 984-992, 2007 | 92 | 2007 |
| Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not … PL Lakatos, I Altorjay, T Szamosi, K Palatka, Z Vitalis, J Tumpek, S Sipka, ... Inflammatory bowel diseases 15 (3), 365-374, 2009 | 89 | 2009 |
| Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised … L Peyrin-Biroulet, A Hart, P Bossuyt, M Long, M Allez, P Juillerat, ... The lancet Gastroenterology & hepatology 7 (2), 128-140, 2022 | 77 | 2022 |
| Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease K Palatka, Z Serfőző, Z Veréb, Z Hargitay, B Lontay, F Erdődi, G Bánfalvi, ... Scandinavian journal of gastroenterology 40 (6), 670-680, 2005 | 77 | 2005 |
| ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients PL Lakatos, T Szamosi, A Szilvasi, E Molnar, L Lakatos, A Kovacs, ... Digestive and liver disease 40 (11), 867-873, 2008 | 76 | 2008 |
| Presence of anti-microbial antibodies in liver cirrhosis–a tell-tale sign of compromised immunity? M Papp, GL Norman, Z Vitalis, I Tornai, I Altorjay, I Foldi, M Udvardy, ... PLoS One 5 (9), e12957, 2010 | 67 | 2010 |
| Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn’s patients: the importance of specific target … M Papp, N Sipeki, T Tornai, I Altorjay, GL Norman, Z Shums, ... Journal of Crohn's and Colitis 9 (8), 659-668, 2015 | 54 | 2015 |
| Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study P Miheller, PL Lakatos, G Horváth, T Molnár, T Szamosi, Z Czeglédi, ... BMC gastroenterology 9, 1-7, 2009 | 53 | 2009 |
